Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.

Item
http://www.wikidata.org/entity/Q33452162
The role of disposable inhalers in pulmonary drug delivery.Faraday instability-based micro droplet ejection for inhalation drug delivery.Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Liposomal formulations for inhalation.Nebulizers for drug delivery to the lungs.Nebulization as a delivery method for mAbs in respiratory diseases.Nebulized drug delivery in respiratory medicine: what does the future hold?The function and performance of aqueous aerosol devices for inhalation therapy.Drug Delivery Devices for Inhaled Medicines.Development and characterization of phospholipid-stabilized submicron aqueous dispersions of coenzyme Q₁₀ presenting continuous vibrating-mesh nebulization performance.Faraday Waves-Based Integrated Ultrasonic Micro-Droplet Generator and Applications.Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments.In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution.MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.On the Development of Focused Ultrasound Liquid Atomizers
P2860

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.

Item
http://www.wikidata.org/entity/Q33452162
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Changes in performance of the ...... g 6 months use by CF patients.
@ast
Changes in performance of the ...... g 6 months use by CF patients.
@en
type
label
Changes in performance of the ...... g 6 months use by CF patients.
@ast
Changes in performance of the ...... g 6 months use by CF patients.
@en
prefLabel
Changes in performance of the ...... g 6 months use by CF patients.
@ast
Changes in performance of the ...... g 6 months use by CF patients.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Changes in performance of the ...... g 6 months use by CF patients.
@en
P2093
P304
P31
P356
P433
P478
P577
P5875
P698